UNITED STATES OF AMERICA —VitriVax has successfully closed an $87 million Series C financing round to propel its lead Lyme disease vaccine candidate into initial human clinical trials. The investment consortium was co-led by F-Prime, NEA, RA Capital Management, and Sanofi Ventures, with additional participation from Eli Lilly and Company. This capital injection is designated to accelerate first-in-human data generation and broaden the organization’s pipeline of proprietary immunization programs.
This development addresses a persistent clinical and commercial vulnerability in current vector-borne disease prevention. Existing late-stage Lyme disease vaccines under development require complex multi-dose primary series and seasonal boosters, a regimen that historically sees up to half of patients discontinuing treatment prematurely. By engineering a single-dose alternative, the company aims to drastically improve patient compliance and real-world efficacy rates across highly endemic regions in North America and Europe.
The broader biotechnology and public health sectors stand to benefit from the underlying Atomic Layering Thermostable Antigen and Adjuvant platform. This formulation technology is engineered to enhance immunogenicity while reducing antigen and adjuvant requirements, thereby lowering manufacturing costs. Furthermore, the platform supports messenger RNA delivery without relying on lipid nanoparticles and minimizes cold-chain dependencies, which is critical for expanding vaccine accessibility in resource-constrained global markets.
Strategically, this funding milestone transitions the entity from a pure technology platform into a fully integrated vaccine development organization. Building upon a previous $17.25 million Series B round and non-dilutive grants from the Gates Foundation, the Coalition for Epidemic Preparedness Innovations, and the United States Department of Defense, the company is now positioned to advance multiple indications. These include ongoing partner-funded initiatives targeting rabies, melioidosis, polio, and HIV, signaling strong institutional confidence in next-generation vaccine economics and global health preparedness.
VitriVax is a Boulder, Colorado-based biotechnology firm specializing in advanced vaccine development and formulation technologies. The organization focuses on creating thermostable, single-dose immunizations designed to overcome traditional logistical and immunological barriers in global healthcare delivery.